Following a gift from Brown trustee Giammaria Giuliani P’28 and Sabrina Giuliani P’28, Brown’s RNA center will be named the ...

SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD ...

City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has ...

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Live webcasts of the analyst-led fireside chats can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Lilly teams up with SanegeneBio in a US$1.2 billion RNAi deal to develop tissue-targeted metabolic therapies using ...

The first sprayable insecticide made of RNA can target and kill ravenous Colorado potato beetles while sparing most ...